JP2014520787A5 - - Google Patents

Download PDF

Info

Publication number
JP2014520787A5
JP2014520787A5 JP2014517822A JP2014517822A JP2014520787A5 JP 2014520787 A5 JP2014520787 A5 JP 2014520787A5 JP 2014517822 A JP2014517822 A JP 2014517822A JP 2014517822 A JP2014517822 A JP 2014517822A JP 2014520787 A5 JP2014520787 A5 JP 2014520787A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014517822A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014520787A (ja
JP6122427B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/063249 external-priority patent/WO2013004818A1/en
Publication of JP2014520787A publication Critical patent/JP2014520787A/ja
Publication of JP2014520787A5 publication Critical patent/JP2014520787A5/ja
Application granted granted Critical
Publication of JP6122427B2 publication Critical patent/JP6122427B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014517822A 2011-07-07 2012-07-06 ダルナビル複合製剤 Active JP6122427B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11173067.7 2011-07-07
EP11173067 2011-07-07
PCT/EP2012/063249 WO2013004818A1 (en) 2011-07-07 2012-07-06 Darunavir combination formulations

Publications (3)

Publication Number Publication Date
JP2014520787A JP2014520787A (ja) 2014-08-25
JP2014520787A5 true JP2014520787A5 (https=) 2015-08-13
JP6122427B2 JP6122427B2 (ja) 2017-04-26

Family

ID=46551505

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014517822A Active JP6122427B2 (ja) 2011-07-07 2012-07-06 ダルナビル複合製剤

Country Status (24)

Country Link
US (3) US20140142070A1 (https=)
EP (1) EP2729130B1 (https=)
JP (1) JP6122427B2 (https=)
KR (1) KR102058097B1 (https=)
CN (1) CN103826616B (https=)
AU (1) AU2012280198B2 (https=)
BR (1) BR112014000290B1 (https=)
CA (1) CA2838659C (https=)
CY (1) CY1121999T1 (https=)
DK (1) DK2729130T3 (https=)
EA (1) EA026587B1 (https=)
ES (1) ES2651212T3 (https=)
HR (1) HRP20171889T1 (https=)
HU (1) HUE035241T2 (https=)
IL (1) IL229933A (https=)
LT (1) LT2729130T (https=)
MX (1) MX343689B (https=)
NO (1) NO2729130T3 (https=)
PL (1) PL2729130T3 (https=)
PT (1) PT2729130T (https=)
RS (1) RS56667B1 (https=)
SI (1) SI2729130T1 (https=)
SM (1) SMT201700574T1 (https=)
WO (1) WO2013004818A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2729130B1 (en) 2011-07-07 2017-09-06 Janssen Sciences Ireland UC Darunavir combination formulations
HK1204980A1 (en) * 2012-03-01 2015-12-11 Gilead Sciences, Inc. Spray dried formulations
EA030003B1 (ru) 2012-12-21 2018-06-29 Джилид Сайэнс, Инк. Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции
WO2017083304A1 (en) 2015-11-09 2017-05-18 Gilead Sciences, Inc. Therapeutic compositions for treatment of human immunodeficiency virus
EP3496710A4 (en) * 2016-08-08 2020-03-18 Hetero Labs Limited TABLET COMPOSITION WITH A HIGH ACTIVE SUBSTANCE LOAD FOR TREATING HIV
ES2952878T3 (es) * 2016-08-08 2023-11-06 Hetero Labs Ltd Una composición antirretroviral multiclase
BR112019002132A2 (pt) 2016-08-08 2019-05-14 Hetero Labs Limited composições anti-retrovirais
WO2018064071A1 (en) * 2016-09-27 2018-04-05 Gilead Sciences, Inc. Therapeutic compositions for treatment of human immunodeficiency virus
EP3654951A1 (en) 2017-07-20 2020-05-27 Janssen Sciences Ireland Unlimited Company Compositions comprising darunavir, cobicistat, emtricitabine and tenofovir alafenamide for use in the treatment of hiv
WO2020064980A1 (en) 2018-09-28 2020-04-02 Janssen Sciences Ireland Unlimited Company Methods of treating and preventing neuropsychiatric and/or neurocognitive complications in patients infected with hiv
US20210290590A1 (en) 2020-03-13 2021-09-23 Janssen Sciences Ireland Unlimited Company Methods of treating subjects infected with hiv
CN119700779B (zh) * 2024-11-28 2025-11-04 安徽贝克生物制药有限公司 一种达芦那韦和考比司他复合片剂及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968942A (en) 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
EP0715618B1 (en) 1993-08-24 1998-12-16 G.D. Searle & Co. Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors
CA2872424C (en) 1998-06-23 2017-03-07 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Bisfuran derivatives useful in preventing the emergence of multidrug resistant hiv strains and treatment of hiv
TWI286476B (en) 2001-12-12 2007-09-11 Tibotec Pharm Ltd Combination of cytochrome P450 dependent protease inhibitors
BRPI0311176B8 (pt) 2002-05-16 2021-05-25 Janssen Sciences Ireland Uc pseudopolimorfo na forma de etanolato, seu uso, processo de preparação do mesmo e composição farmacêutica
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
WO2007143422A2 (en) 2006-05-30 2007-12-13 Janssen Pharmaceutica N.V. Substituted pyridyl amide compounds as modulators of the histamine h3 receptor
US20080039428A1 (en) * 2006-06-29 2008-02-14 Panacos Pharmaceuticals, Inc. Antiretroviral combination therapy
PL2049506T5 (pl) 2006-07-07 2024-09-09 Gilead Sciences, Inc. Modulatory farmakokinetycznych właściwości leków
CA2667207A1 (en) * 2006-10-25 2008-05-02 Mcneil-Ppc, Inc. Ibuprofen composition
MX2009008935A (es) 2007-02-23 2009-11-02 Gilead Sciences Inc Moduladores de las propiedades farmacocineticas de productos terapeuticos.
JP2010531301A (ja) * 2007-06-25 2010-09-24 テイボテク・フアーマシユーチカルズ ダルナビル及びエトラビリンを含んでなる組み合わせ調剤
AR069539A1 (es) 2007-07-25 2010-02-03 Tibotec Pharm Ltd Avances respecto de las formulaciones de comprimidos contra el vih
CN101868454A (zh) 2007-11-20 2010-10-20 詹森药业有限公司 作为组胺h3受体调节剂的环烷基氧基吡啶化合物和杂环烷基氧基吡啶化合物
GT200800303A (es) * 2007-12-24 2009-09-18 Combinacion anti-retroviral
MX2010011963A (es) * 2008-05-02 2010-12-06 Gilead Sciences Inc Uso de particulas trasportadoras solidas para mejorar la capacidad de procesamiento de un agente farmaceutico.
EP2393485B1 (en) * 2009-02-06 2015-07-29 Gilead Sciences, Inc. Bilayer tablets comprising elvitegravir, cobicistat, emtricitabine and tenofovir
CA2776807C (en) * 2009-09-17 2018-10-16 Mylan Laboratories Limited An improved process for the preparation of darunavir
US20130195978A1 (en) 2010-05-10 2013-08-01 Hetero Research Foundation Darunavir Compositions
EP2729130B1 (en) 2011-07-07 2017-09-06 Janssen Sciences Ireland UC Darunavir combination formulations
SI2729128T1 (sl) 2011-07-07 2016-11-30 Janssen Sciences Ireland Uc Formulacije darunavirja
AU2012327170A1 (en) 2012-02-03 2013-08-22 Gilead Sciences, Inc. Therapeutic compounds
AU2015373104B2 (en) 2015-01-03 2020-07-09 Mylan Laboratories Limited Processes for the preparation of amorphous tenofovir alafenamide hemifumarate and a premix thereof

Similar Documents

Publication Publication Date Title
JP2011093937A5 (https=)
JP2013539946A5 (https=)
JP2013531034A5 (https=)
JP2013531018A5 (https=)
JP2014503786A5 (https=)
JP2012023335A5 (https=)
JP2014026276A5 (https=)
JP2014026275A5 (https=)
JP2014026274A5 (https=)
JP2014505137A5 (https=)
JP2015500269A5 (https=)
JP2013064178A5 (https=)
JP2012204203A5 (https=)
JP2014189812A5 (https=)
JP2014520787A5 (https=)
JP2015107586A5 (https=)
JP2012193264A5 (https=)
JP2012190699A5 (https=)
JP2014531903A5 (https=)
JP2014534151A5 (https=)
JP2014520786A5 (https=)
JP2011233516A5 (https=)
JP2014005521A5 (https=)
JP2013016377A5 (https=)
JP2015127764A5 (https=)